Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Enabling the industrialization of human induced pluripotent stem cell-based therapies

Sponsored by:

Lonza Pharma & Biotech

Human induced pluripotent stem cells (iPSCs) offer a promising and unlimited source of cells for curative cell replacement therapies in the treatment of devastating diseases such as Parkinson’s disease (PD) and diabetes.

However, in order to commercialize these therapies to treat a large number of individuals at affordable costs, it is necessary to demonstrate the safety and efficacy of these therapies and industrialize the manufacturing process for iPSC-derived functional cells in a scalable and controlled manner.

This webinar provides a checklist of the major steps we have taken at Lonza towards the industrialization of iPSC-derived cell therapy products with focus on the development of a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process, characterization of iPSCs, development of scalable, computer-controlled bioprocessing system for expansion and / or directed differentiation of human iPSC using microcarrier-based and carrier-free strategies.

Key learning points include:



Krishna Panchalingam

Dr Krishna Panchalingam, PhD,  Senior Scientist, Cell and Gene Therapy Process Development Group, Emerging Technologies, Lonza Pharma & Biotech

Dr. Panchalingam is a Senior Scientist in the Cell and Gene Therapy Process Development group, Emerging Technologies at Lonza. He has over 14 years of experience in stem cell bioengineering, bioprocessing and in the cell and gene therapy field. Dr. Panchalingam holds a PhD degree in Chemical Engineering from the University of Calgary (Calgary, Canada) where he focused on the development of viable, scalable, and defined bioprocesses in the field of regenerative medicine.

After completing his PhD, Dr. Panchalingam started as a Bioprocess Scientist/Engineer at CCRM (Toronto, Canada), leading the development and optimization of large-scale immune cell and iPSC-based manufacturing processes and the controlled differentiation of iPSCs to cardiomyocytes.

Since joining Lonza in 2016, Dr. Panchalingam has been leading the development of new technologies and robust manufacturing processes for the clinical manufacturing of next generation cell and gene therapies.



Inbar Friedrich Ben-Nun

Inbar Friedrich Ben-Nun, PhD, Senior R&D Manager for Cell & Gene Technologies, Lonza Pharma & Biotech

Dr. Inbar Friedrich Ben-Nun is a Sr. Manager in the Cell and Gene Therapy R&D at Lonza. Inbar obtained her PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work published in “Nature Methods” showed for the first time that stem cell research could be apply to save species from extinction. Inbar has joined Lonza in 2011, and in her current role she leads a team that focuses on developing innovative solutions to enable stem cell-based therapies.



Marcos Langtry

Marcos Langtry, Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

 

The Lonza logo is a Lonza Ltd. Trademark

Twitter IconVisit Our Blog